Business
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package Patients completing the ongoing Halneuron® 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medi
About this update from Dogwood Therapeutics, Inc.
[{"type":"image","alt":"Dogwood Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Dogwood Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5oqVaVpm5SX3iW1kYFN9Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/5oqVaVpm5SX3iW1kYFN9Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/31af9905c689ad6d0133d00b8d554d8f","width":300,"height":300}},"lazy":false},{"type":"text","content":"New study to assess Halneuron® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package","length":164,"tagName":"p"},{"type":"text","content":"Patients completing the ongoing Halneuron® 4-week CINP Phase 2b study are now eligible to enroll in the new 12-week open-label follow-on trial ","length":142,"tagName":"p"},{"type":"text","content":"ALPHARETTA, Ga., May 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“Dogwood” or the “Company”), a biopharmaceutical company developing first-in-class, non-opioid medicines to treat pain and neuropathy, today announced commencement of a new Halneuron® chemotherapy induced neuropathic pain (“CINP”) phase 2b extension study. Based on a positive interim assessment demonstrating a Halneuron® 4-week treatment effect versus placebo, Dogwood previously submitted plans to FDA to support commencement of a Halneuron® 12-week follow-on open-label extension study for patients completing the 4-week double-blinded treatment period. Several patients have already been enrolled in the new study that will assess the safety and efficacy of continued Halneuron® treatment for an additional 3 months, using various dosing regimens. Data from the forthcoming extension trial will add to the data package the Company plans to submit to the FDA to support its planned Phase 3 development program, presently projected to start in the first half of 2027.","length":1063,"tagName":"p"},{"type":"text","content":"Dogwood Therapeutics previously announced that a pre-planned interim a...